TP53 and neuroendocrine carcinoma: As can be seen from Fig. 8G and Additional file 3: Figure S3G, the tissues of patients with neuroendocrine carcinoma can detect more mutated genes than arterial CTCs and venous CTCs, and multiple mutated genes (TP53, KIT, BRCA1, ATM) targeted with clinically available drugs were detected in tissues.